Japanese subgroup analysis in the Asian phase II study of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma
Eiju Negoro(University of Fukui Hospital), Kensei Tobinai(National Cancer Center), Nobuhiko Nakamura(Gifu University Hospital), Yok‐Lam Kwong(Queen Mary Hospital), Kazuhito Yamamoto(Aichi Cancer Center), Yoshinobu Maeda(Okayama University Hospital), Koji Izutsu(Tokyo National Hospital), Hwei‐Fang Tien(Far Eastern Memorial Hospital), Dai Maruyama(National Cancer Center), Noriko Fukuhara(Tohoku University Hospital), Hirohiko Shibayama(Osaka National Hospital), Toshiki Uchida(Red Cross Hospital), Fumiko Nagahama, Takahiro Yamauchi(University of Fukui Hospital), Yusuke Sonehara, Ilseung Choi(National Hospital Organization Kyushu Cancer Center), Hirokazu Nagai(Tokai University), Go Yamamoto(Toranomon Hospital), Kiyoshi Ando(Hiroshima University), Yasuhito Terui(Saitama Medical University Hospital), Won-Seog Kim(Samsung Medical Center), Nobuhiro Kanemura(Gifu University Hospital), Youko Suehiro(National Hospital Organization Kyushu Cancer Center), Hideaki Nakajima(Yokohama City University Hospital)
Cited by 3
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project
|Blood|2011|431
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma
|New England Journal of Medicine|2022|342